Drug Detail:Patiromer (Patiromer [ pat-i-roe-mer ])
Drug Class: Cation exchange resins
Usual Adult Dose for Hyperkalemia
Initial dose: 8.4 g orally once a day
- Monitor serum potassium level and adjust dose in 8.4 mg increments at 1-week intervals based on serum potassium level and desired target range
Maximum dose 25.2 g/day
Comments:
- This drug should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
- This drug should be administered at least 3 hours before or 3 hours after other oral medications.
Use: For the treatment of hyperkalemia.
Renal Dose Adjustments
No dosing adjustments recommended
Liver Dose Adjustments
No dosing adjustments recommended
Precautions
CONTRAINDICATIONS:
- Hypersensitivity to the active component or any of the ingredients
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Take orally once a day
- Do not take in its dry form; do not heat in microwave or add to heated foods or liquids
- Prepare each dose immediately prior to administration
- Separate administration of this drug by 3 hours (before or after) from other drugs
Storage requirements:
- Store in the refrigerator at 2C to 8C (36F to 46F).
- Use within 3 months if stored at room temperature (25C [77F])
- Avoid exposure to heat above 40C (104F).
Reconstitution/preparation techniques:
Prepare each dose immediately prior to administration following the steps below:
- Measure 30 mL of water; pour half of the water into a glass and add prescribed packet(s) and stir; add remaining water and stir thoroughly; the powder will not dissolve, and the mixture will look cloudy
- Additional water may be added as desired; apple juice or cranberry juice may be used instead of water
- Consume immediately, if powder remains in the glass, add more water, stir, and drink immediately, repeating as needed to ensure the entire dose is administered
General:
- In clinical trials 93% of patients had chronic kidney disease; no special dosing adjustments are needed for patients with renal impairment.
Monitoring:
- Monitor potassium levels
- Monitor magnesium levels
Patient advice:
- Patients should be instructed on proper preparation of this drug; they should understand that this drug should not be heated (e.g., microwaved) or added to heated foods or liquids and should not be taken in its dry form.
- Patients should be instructed to adhere to their prescribed diets.
- Patients taking other oral medications should separate the dosing of this drug by at least 3 hours (before or after).
